170 related articles for article (PubMed ID: 21246525)
1. A phase 2 trial of bortezomib followed by the addition of doxorubicin at progression in patients with recurrent or metastatic adenoid cystic carcinoma of the head and neck: a trial of the Eastern Cooperative Oncology Group (E1303).
Argiris A; Ghebremichael M; Burtness B; Axelrod RS; Deconti RC; Forastiere AA
Cancer; 2011 Aug; 117(15):3374-82. PubMed ID: 21246525
[TBL] [Abstract][Full Text] [Related]
2. Phase II trial of bortezomib plus doxorubicin in hepatocellular carcinoma (E6202): a trial of the Eastern Cooperative Oncology Group.
Ciombor KK; Feng Y; Benson AB; Su Y; Horton L; Short SP; Kauh JS; Staley C; Mulcahy M; Powell M; Amiri KI; Richmond A; Berlin J
Invest New Drugs; 2014 Oct; 32(5):1017-27. PubMed ID: 24890858
[TBL] [Abstract][Full Text] [Related]
3. Phase II 2-arm trial of the proteasome inhibitor, PS-341 (bortezomib) in combination with irinotecan or PS-341 alone followed by the addition of irinotecan at time of progression in patients with locally recurrent or metastatic squamous cell carcinoma of the head and neck (E1304): a trial of the Eastern Cooperative Oncology Group.
Gilbert J; Lee JW; Argiris A; Haigentz M; Feldman LE; Jang M; Arun P; Van Waes C; Forastiere AA
Head Neck; 2013 Jul; 35(7):942-8. PubMed ID: 22791234
[TBL] [Abstract][Full Text] [Related]
4. Clinical trial of nintedanib in patients with recurrent or metastatic salivary gland cancer of the head and neck: A multicenter phase 2 study (Korean Cancer Study Group HN14-01).
Kim Y; Lee SJ; Lee JY; Lee SH; Sun JM; Park K; An HJ; Cho JY; Kang EJ; Lee HY; Kim J; Keam B; Kim HR; Lee KE; Choi MY; Lee KH; Ahn MJ
Cancer; 2017 Jun; 123(11):1958-1964. PubMed ID: 28102887
[TBL] [Abstract][Full Text] [Related]
5. Nuclear factor-kappa B pathway and response in a phase II trial of bortezomib and docetaxel in patients with recurrent and/or metastatic head and neck squamous cell carcinoma.
Chung CH; Aulino J; Muldowney NJ; Hatakeyama H; Baumann J; Burkey B; Netterville J; Sinard R; Yarbrough WG; Cmelak AJ; Slebos RJ; Shyr Y; Parker J; Gilbert J; Murphy BA
Ann Oncol; 2010 Apr; 21(4):864-870. PubMed ID: 19850643
[TBL] [Abstract][Full Text] [Related]
6. Phase I study of two different schedules of bortezomib and pemetrexed in advanced solid tumors with emphasis on non-small cell lung cancer.
Davies AM; Ho C; Metzger AS; Beckett LA; Christensen S; Tanaka M; Lara PN; Lau DH; Gandara DR
J Thorac Oncol; 2007 Dec; 2(12):1112-6. PubMed ID: 18090584
[TBL] [Abstract][Full Text] [Related]
7. Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression.
Orlowski RZ; Nagler A; Sonneveld P; Bladé J; Hajek R; Spencer A; San Miguel J; Robak T; Dmoszynska A; Horvath N; Spicka I; Sutherland HJ; Suvorov AN; Zhuang SH; Parekh T; Xiu L; Yuan Z; Rackoff W; Harousseau JL
J Clin Oncol; 2007 Sep; 25(25):3892-901. PubMed ID: 17679727
[TBL] [Abstract][Full Text] [Related]
8. Bortezomib plus rituximab versus rituximab alone in patients with relapsed, rituximab-naive or rituximab-sensitive, follicular lymphoma: a randomised phase 3 trial.
Coiffier B; Osmanov EA; Hong X; Scheliga A; Mayer J; Offner F; Rule S; Teixeira A; Walewski J; de Vos S; Crump M; Shpilberg O; Esseltine DL; Zhu E; Enny C; Theocharous P; van de Velde H; Elsayed YA; Zinzani PL;
Lancet Oncol; 2011 Aug; 12(8):773-84. PubMed ID: 21724462
[TBL] [Abstract][Full Text] [Related]
9. An open-label phase 2 study of twice-weekly bortezomib and intermittent pegylated liposomal doxorubicin in patients with ovarian cancer failing platinum-containing regimens.
Parma G; Mancari R; Del Conte G; Scambia G; Gadducci A; Hess D; Katsaros D; Sessa C; Rinaldi A; Bertoni F; Vitali A; Catapano CV; Marsoni S; van de Velde H; Colombo N
Int J Gynecol Cancer; 2012 Jun; 22(5):792-800. PubMed ID: 22635029
[TBL] [Abstract][Full Text] [Related]
10. Cisplatin-based chemotherapy in advanced adenoid cystic carcinoma of the head and neck.
de Haan LD; De Mulder PH; Vermorken JB; Schornagel JH; Vermey A; Verweij J
Head Neck; 1992; 14(4):273-7. PubMed ID: 1381339
[TBL] [Abstract][Full Text] [Related]
11. Phase II study of bortezomib and pegylated liposomal doxorubicin in the treatment of metastatic breast cancer.
Irvin WJ; Orlowski RZ; Chiu WK; Carey LA; Collichio FA; Bernard PS; Stijleman IJ; Perou C; Ivanova A; Dees EC
Clin Breast Cancer; 2010 Dec; 10(6):465-70. PubMed ID: 21147690
[TBL] [Abstract][Full Text] [Related]
12. A phase I pharmacodynamic trial of bortezomib in combination with doxorubicin in patients with advanced cancer.
LoConte NK; Thomas JP; Alberti D; Heideman J; Binger K; Marnocha R; Utecht K; Geiger P; Eickhoff J; Wilding G; Kolesar J
Cancer Chemother Pharmacol; 2008 Dec; 63(1):109-15. PubMed ID: 18322686
[TBL] [Abstract][Full Text] [Related]
13. A phase I and pharmacologic study of the combination of bortezomib and pegylated liposomal doxorubicin in patients with refractory solid tumors.
Dees EC; O'Neil BH; Lindley CM; Collichio F; Carey LA; Collins J; Riordan WJ; Ivanova A; Esseltine D; Orlowski RZ
Cancer Chemother Pharmacol; 2008 Dec; 63(1):99-107. PubMed ID: 18327587
[TBL] [Abstract][Full Text] [Related]
14. Phase 1 trial of the proteasome inhibitor bortezomib and pegylated liposomal doxorubicin in patients with advanced hematologic malignancies.
Orlowski RZ; Voorhees PM; Garcia RA; Hall MD; Kudrik FJ; Allred T; Johri AR; Jones PE; Ivanova A; Van Deventer HW; Gabriel DA; Shea TC; Mitchell BS; Adams J; Esseltine DL; Trehu EG; Green M; Lehman MJ; Natoli S; Collins JM; Lindley CM; Dees EC
Blood; 2005 Apr; 105(8):3058-65. PubMed ID: 15626743
[TBL] [Abstract][Full Text] [Related]
15. Phase II study of the proteasome inhibitor bortezomib (PS-341, Velcade) in chemotherapy-naïve patients with advanced stage non-small cell lung cancer (NSCLC).
Li T; Ho L; Piperdi B; Elrafei T; Camacho FJ; Rigas JR; Perez-Soler R; Gucalp R
Lung Cancer; 2010 Apr; 68(1):89-93. PubMed ID: 19524318
[TBL] [Abstract][Full Text] [Related]
16. A study of paclitaxel, carboplatin, and bortezomib in the treatment of metastatic malignant melanoma: a phase 2 consortium study.
Croghan GA; Suman VJ; Maples WJ; Albertini M; Linette G; Flaherty L; Eckardt J; Ma C; Markovic SN; Erlichman C
Cancer; 2010 Jul; 116(14):3463-8. PubMed ID: 20564112
[TBL] [Abstract][Full Text] [Related]
17. A phase 1 dose escalation study of bortezomib combined with rituximab, cyclophosphamide, doxorubicin, modified vincristine, and prednisone for untreated follicular lymphoma and other low-grade B-cell lymphomas.
Sinha R; Kaufman JL; Khoury HJ; King N; Shenoy PJ; Lewis C; Bumpers K; Hutchison-Rzepka A; Tighiouart M; Heffner LT; Lechowicz MJ; Lonial S; Flowers CR
Cancer; 2012 Jul; 118(14):3538-48. PubMed ID: 22535574
[TBL] [Abstract][Full Text] [Related]
18. Phase I trial using the proteasome inhibitor bortezomib and concurrent chemoradiotherapy for head-and-neck malignancies.
Kubicek GJ; Axelrod RS; Machtay M; Ahn PH; Anne PR; Fogh S; Cognetti D; Myers TJ; Curran WJ; Dicker AP
Int J Radiat Oncol Biol Phys; 2012 Jul; 83(4):1192-7. PubMed ID: 22245208
[TBL] [Abstract][Full Text] [Related]
19. A phase I trial of bortezomib with temozolomide in patients with advanced melanoma: toxicities, antitumor effects, and modulation of therapeutic targets.
Su Y; Amiri KI; Horton LW; Yu Y; Ayers GD; Koehler E; Kelley MC; Puzanov I; Richmond A; Sosman JA
Clin Cancer Res; 2010 Jan; 16(1):348-57. PubMed ID: 20028756
[TBL] [Abstract][Full Text] [Related]
20. Bortezomib (PS-341) in relapsed or refractory extensive stage small cell lung cancer: a Southwest Oncology Group phase II trial (S0327).
Lara PN; Chansky K; Davies AM; Franklin WA; Gumerlock PH; Guaglianone PP; Atkins JN; Farneth N; Mack PC; Crowley JJ; Gandara DR
J Thorac Oncol; 2006 Nov; 1(9):996-1001. PubMed ID: 17409985
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
